{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T18:00:32Z","timestamp":1785002432712,"version":"3.55.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,25]]},"DOI":"10.7759\/cureus.113358","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T17:04:34Z","timestamp":1784999074000},"source":"Crossref","is-referenced-by-count":0,"title":["Impact of the 21-Gene Oncotype DX Recurrence Score on Adjuvant Chemotherapy Decision-Making in Invasive Ductal Carcinoma: A Real-World Analysis From a Single Japanese Institution"],"prefix":"10.7759","author":[{"given":"Hirofumi","family":"Terakawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Mohri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyuki","family":"Inaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1804710","article-title":"Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer","volume":"379","author":"Sparano JA","year":"2018","unstructured":"Sparano JA, Gray RJ, Makower DF, et al.. Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med. 2018, 379:111-21. 10.1056\/NEJMoa1804710","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.2289","article-title":"Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline","volume":"34","author":"Harris LN","year":"2016","unstructured":"Harris LN, Ismaila N, McShane LM, et al.. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016, 34:1134-50. 10.1200\/JCO.2015.65.2289","journal-title":"J Clin Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00069","article-title":"Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update","volume":"40","author":"Andre F","year":"2022","unstructured":"Andre F, Ismaila N, Allison KH, et al.. Biomarkers for adjuvant endocrine and chemotherapy in early-stage breast cancer: ASCO guideline update. J Clin Oncol. 2022, 40:1816-37. 10.1200\/JCO.22.00069","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03007","article-title":"Development and validation of a tool integrating the 21-gene recurrence score and clinical-pathological features to individualize prognosis and prediction of chemotherapy benefit in early breast cancer","volume":"39","author":"Sparano JA","year":"2021","unstructured":"Sparano JA, Crager MR, Tang G, Gray RJ, Stemmer SM, Shak S. Development and validation of a tool integrating the 21-gene recurrence score and clinical-pathological features to individualize prognosis and prediction of chemotherapy benefit in early breast cancer. J Clin Oncol. 2021, 39:557-64. 10.1200\/JCO.20.03007","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1904819","article-title":"Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer","volume":"380","author":"Sparano JA","year":"2019","unstructured":"Sparano JA, Gray RJ, Ravdin PM, et al.. Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer. N Engl J Med. 2019, 380:2395-405. 10.1056\/NEJMoa1904819","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108873","article-title":"21-gene assay to inform chemotherapy benefit in node-positive breast cancer","volume":"385","author":"Kalinsky K","year":"2021","unstructured":"Kalinsky K, Barlow WE, Gralow JR, et al.. 21-gene assay to inform chemotherapy benefit in node-positive breast cancer. N Engl J Med. 2021, 385:2336-47. 10.1056\/NEJMoa2108873","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602253","article-title":"70-gene signature as an aid to treatment decisions in early-stage breast cancer","volume":"375","author":"Cardoso F","year":"2016","unstructured":"Cardoso F, van't Veer LJ, Bogaerts J, et al.. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016, 375:717-29. 10.1056\/NEJMoa1602253","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00007-3","article-title":"70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age","volume":"22","author":"Piccart M","year":"2021","unstructured":"Piccart M, van \u2019t Veer LJ, Poncet C, et al.. 70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. Lancet Oncol. 2021, 22:476-88. 10.1016\/S1470-2045(21)00007-3","journal-title":"Lancet Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.08.017","article-title":"Understanding breast cancer complexity to improve patient outcomes: the St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023","volume":"34","author":"Curigliano G","year":"2023","unstructured":"Curigliano G, Burstein HJ, Gnant M, et al.. Understanding breast cancer complexity to improve patient outcomes: the St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023. Ann Oncol. 2023, 34:970-86. 10.1016\/j.annonc.2023.08.017","journal-title":"Ann Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.1991.tb00229.x","article-title":"Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up","volume":"19","author":"Elston CW","year":"1991","unstructured":"Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991, 19:403-10. 10.1111\/j.1365-2559.1991.tb00229.x","journal-title":"Histopathology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02309","article-title":"Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update","volume":"38","author":"Allison KH","year":"2020","unstructured":"Allison KH, Hammond ME, Dowsett M, et al.. Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP guideline update. J Clin Oncol. 2020, 38:1346-66. 10.1200\/JCO.19.02309","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update","volume":"36","author":"Wolff AC","year":"2018","unstructured":"Wolff AC, Hammond ME, Allison KH, et al.. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update. J Clin Oncol. 2018, 36:2105-22. 10.1200\/JCO.2018.77.8738","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaa201","article-title":"Assessment of Ki67 in breast cancer: updated recommendations from the International Ki67 in Breast Cancer Working Group","volume":"113","author":"Nielsen TO","year":"2021","unstructured":"Nielsen TO, Leung SC, Rimm DL, et al.. Assessment of Ki67 in breast cancer: updated recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 2021, 113:808-19. 10.1093\/jnci\/djaa201","journal-title":"J Natl Cancer Inst"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.11470","article-title":"Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial","volume":"318","author":"Giuliano AE","year":"2017","unstructured":"Giuliano AE, Ballman KV, McCall L, et al.. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017, 318:918-26. 10.1001\/jama.2017.11470","journal-title":"JAMA"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.002","article-title":"Impact of anthracyclines in genomic high-risk, node-negative, HR-positive\/HER2-negative breast cancer","volume":"36","author":"Chen N","year":"2025","unstructured":"Chen N, Freeman JQ, Yarlagadda S, et al.. Impact of anthracyclines in genomic high-risk, node-negative, HR-positive\/HER2-negative breast cancer. Ann Oncol. 2025, 36:1356-65. 10.1016\/j.annonc.2025.08.002","journal-title":"Ann Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.104085","article-title":"Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid\u00a0+ letrozole in premenopausal hormone receptor-positive early breast cancer patients","volume":"10","author":"Gravina A","year":"2025","unstructured":"Gravina A, Gargiulo P, De Laurentiis M, et al.. Ten-year update of HOBOE phase III trial comparing triptorelin plus either tamoxifen or letrozole or zoledronic acid\u00a0+ letrozole in premenopausal hormone receptor-positive early breast cancer patients. ESMO Open. 2025, 10:104085. 10.1016\/j.esmoop.2024.104085","journal-title":"ESMO Open"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1159\/000488026","article-title":"Adjuvant dose-dense chemotherapy for breast cancer: available evidence and recent updates","volume":"13","author":"de Almeida FK","year":"2018","unstructured":"de Almeida FK, Rosa DD. Adjuvant dose-dense chemotherapy for breast cancer: available evidence and recent updates. Breast Care (Basel). 2018, 13:447-52. 10.1159\/000488026","journal-title":"Breast Care (Basel)"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30534-9","article-title":"Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Toi M","year":"2021","unstructured":"Toi M, Imoto S, Ishida T, et al.. Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021, 22:74-84. 10.1016\/S1470-2045(20)30534-9","journal-title":"Lancet Oncol"},{"key":"ref19","unstructured":"The R Project for Statistical Computing. (2025). Accessed. June 12, 2026: https:\/\/www.R-project.org\/."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s12282-024-01566-6","article-title":"The Japanese Breast Cancer Society clinical practice guidelines for breast cancer, 2022 edition: changes from the 2018 edition and general statements on breast cancer treatment","volume":"31","author":"Yamamoto Y","year":"2024","unstructured":"Yamamoto Y, Yamauchi C, Toyama T, et al.. The Japanese Breast Cancer Society clinical practice guidelines for breast cancer, 2022 edition: changes from the 2018 edition and general statements on breast cancer treatment. Breast Cancer. 2024, 31:340-6. 10.1007\/s12282-024-01566-6","journal-title":"Breast Cancer"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-018-0082-6","article-title":"Clinical relevance of the 21-gene Recurrence Score(\u00ae) assay in treatment decisions for patients with node-positive breast cancer in the genomic era","volume":"4","author":"Mamounas EP","year":"2018","unstructured":"Mamounas EP, Russell CA, Lau A, Turner MP, Albain KS. Clinical relevance of the 21-gene Recurrence Score(\u00ae) assay in treatment decisions for patients with node-positive breast cancer in the genomic era. NPJ Breast Cancer. 2018, 4:27. 10.1038\/s41523-018-0082-6","journal-title":"NPJ Breast Cancer"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/507994-impact-of-the-21-gene-oncotype-dx-recurrence-score-on-adjuvant-chemotherapy-decision-making-in-invasive-ductal-carcinoma-a-real-world-analysis-from-a-single-japanese-institution","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T17:04:36Z","timestamp":1784999076000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/507994-impact-of-the-21-gene-oncotype-dx-recurrence-score-on-adjuvant-chemotherapy-decision-making-in-invasive-ductal-carcinoma-a-real-world-analysis-from-a-single-japanese-institution"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":21,"URL":"https:\/\/doi.org\/10.7759\/cureus.113358","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,25]]}}}